What empiric antibiotic regimen, dosing, and duration are recommended for intra‑abdominal infections, including options for severe or health‑care‑associated cases, ESBL prevalence, penicillin allergy, and renal impairment?

Empiric Antibiotic Therapy for Intra-Abdominal Infections

Community-Acquired Mild-to-Moderate Infections

For immunocompetent adults with community-acquired intra-abdominal infections of mild-to-moderate severity (e.g., perforated appendicitis, acute diverticulitis), use single-agent therapy with ertapenem 1g IV daily, cefoxitin 2g IV q6h, moxifloxacin 400mg IV daily, or combination therapy with metronidazole 500mg IV q8h plus ceftriaxone 1-2g IV daily, cefuroxime 1.5g IV q8h, or levofloxacin 750mg IV daily. 1

Key Coverage Requirements

• Gram-negative coverage must include E. coli and other Enterobacteriaceae (the most common pathogen, isolated in 71% of cases) 1
• Anaerobic coverage is mandatory for distal small bowel, appendiceal, and colon-derived infections, targeting Bacteroides fragilis (present in 35% of cases) 1
• Gram-positive streptococci coverage is required, though empiric enterococcal coverage is NOT necessary 1

Duration

• 4 days of therapy for immunocompetent patients with adequate source control 2
• Reassess at day 4 and discontinue if clinically improved with adequate drainage 2

Critical Agents to AVOID

• Do NOT use ampicillin-sulbactam due to high E. coli resistance rates (>20% in most communities) 1, 2
• Do NOT use cefotetan or clindamycin due to increasing Bacteroides fragilis resistance 1, 2
• Avoid fluoroquinolones if local E. coli resistance exceeds 10-20% or if the patient received quinolones within 3 months 1

---

Community-Acquired High-Severity Infections

For patients with severe physiologic disturbance, advanced age, immunocompromised state, or high APACHE II scores, use broad-spectrum agents: piperacillin-tazobactam 3.375-4.5g IV q6h, meropenem 1g IV q8h, imipenem-cilastatin 500mg IV q6h, or doripenem 500mg IV q8h. 1

Additional Coverage Considerations

• Empiric enterococcal coverage IS recommended for high-severity infections using ampicillin, piperacillin-tazobactam, or vancomycin 1
• Do NOT routinely add aminoglycosides unless resistant organisms are documented, as less toxic alternatives are equally effective 1
• Empiric antifungal therapy is NOT recommended unless Candida is isolated from cultures 1

Duration

• Up to 7 days for critically ill or immunocompromised patients with adequate source control 2, 3

---

Health Care-Associated Infections

For health care-associated intra-abdominal infections, empiric therapy must be driven by local antibiograms and should include carbapenems (meropenem 1g IV q8h, imipenem-cilastatin 500mg IV q6h, or doripenem 500mg IV q8h) as first-line agents when ESBL-producing organisms, multidrug-resistant Pseudomonas aeruginosa, or Acinetobacter prevalence exceeds 20%. 1, 3

Tailored Coverage Based on Local Resistance

• For ESBL-producing Enterobacteriaceae: Use carbapenems OR piperacillin-tazobactam 4.5g IV q6h plus metronidazole 500mg IV q8h 1
• For Pseudomonas with >20% ceftazidime resistance: Add aminoglycoside (gentamicin 5-7mg/kg IV daily) 1
• For MRSA risk (known colonization, prior treatment failure, significant antibiotic exposure): Add vancomycin 15-20mg/kg IV q8-12h 1, 3
• For enterococcal coverage: Required in postoperative infections, prior cephalosporin use, immunocompromised patients, or valvular heart disease—use ampicillin or piperacillin-tazobactam 1

Antifungal Therapy

• Add fluconazole 400mg IV daily if Candida is grown from cultures in severe community-acquired or health care-associated infections 1
• Use echinocandin (caspofungin 70mg loading, then 50mg IV daily) for fluconazole-resistant species or critically ill patients 1

Duration and De-escalation

• Obtain cultures before initiating therapy to guide de-escalation 1
• Narrow therapy at 3-5 days based on culture results and clinical improvement 1, 3
• Limit therapy to 4-7 days with adequate source control 2, 3

---

Special Populations

ESBL Prevalence Areas

In regions with high ESBL prevalence (>10-20% of E. coli isolates), avoid third-generation cephalosporins and fluoroquinolones for empiric therapy; use carbapenems or piperacillin-tazobactam instead. 1, 4

Penicillin Allergy

For beta-lactam allergic patients, use eravacycline or tigecycline 100mg IV loading, then 50mg IV q12h, OR fluoroquinolone (if local susceptibility >90%) plus metronidazole. 2

Renal Impairment

• Ertapenem: Reduce to 500mg IV daily if CrCl <30 mL/min 1
• Meropenem/Imipenem: Dose-adjust based on CrCl (consult package insert for specific adjustments) 3
• Avoid aminoglycosides in renal impairment unless no alternatives exist; monitor levels closely 1

Pediatric Patients (≥2 months)

Use piperacillin-tazobactam 300-400mg/kg/day divided q6-8h, cefepime 150mg/kg/day divided q8h, meropenem 60mg/kg/day divided q8h, or ceftriaxone 50-75mg/kg/day plus metronidazole 30mg/kg/day divided q6h. 1, 2

---

Common Pitfalls

• Inadequate source control is the most common cause of treatment failure despite appropriate antibiotics—ensure drainage or surgical intervention is adequate 3
• Overuse of carbapenems in mild-moderate community-acquired infections drives carbapenem resistance; reserve for high-severity or health care-associated cases 1, 4
• Failure to obtain cultures in high-risk patients prevents appropriate de-escalation and prolongs broad-spectrum therapy unnecessarily 1
• Continuing antibiotics beyond 4-7 days with adequate source control increases toxicity and resistance without improving outcomes 2, 3